Critical reappraisal of remdesivir investigational trials in COVID-19 | Zendy

Philippe Brouqui | Zendy; Audrey GiraudGatineau | Zendy; Didier Raoult | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Critical reappraisal of remdesivir investigational trials in COVID-19

Author(s) -

Philippe Brouqui,

Audrey GiraudGatineau,

Didier Raoult

Publication year - 2020

Publication title -

new microbes and new infections

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.599

H-Index - 26

ISSN - 2052-2975

DOI - 10.1016/j.nmni.2020.100745

Subject(s) - covid-19 , pandemic , investigational drugs , medicine , clinical trial , intensive care medicine , intervention (counseling) , outbreak , disease , virology , infectious disease (medical specialty) , pathology , nursing

During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention during the COVID-19 pandemic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research